2020年ASCO-SITC:真实世界中淋巴瘤免疫疗法的不良事件发生率高于临床试验

2020-02-12 Allan MedSci原创

根据2020年ASCO上发表的一项研究,在真实世界中,接受免疫疗法治疗的霍奇金淋巴瘤患者的不良事件发生率远高于临床试验。

根据2020ASCO上发表的一项研究,在真实世界中,接受免疫疗法治疗的霍奇金淋巴瘤患者的不良事件发生率远高于临床试验。在临床试验中,不良反应发生率在28%至36%之间。然而,明尼苏达州罗切斯特市梅奥诊所的医学博士Alexandra Higgins报告说:在梅奥诊所,不良事件发生率高达61%。霍奇金淋巴瘤患者免疫治疗相关不良事件的发生率高于临床试验,其特点是发病延迟和持续时间长。但是,很少有因免疫疗法相关的不良事件而中断治疗的情况

研究人员确定了51名被诊断为霍奇金淋巴瘤并接受免疫检查点抑制剂治疗的患者。从治疗开始到随访的中位时间为30个月。在这些患者中,有31名(61%)经历了至少1次与免疫治疗相关的不良事件。最常见的不良事件是炎症性/大块性皮肤病。从治疗开始到不良事件发生的中位时间为81天。患者经历不良事件的中位时间为57天。


原始出处:

https://www.firstwordpharma.com/node/1699229

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1826572, encodeId=c33818265e25f, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Fri May 29 15:10:00 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910541, encodeId=d5221910541cb, content=<a href='/topic/show?id=faf7163606a' target=_blank style='color:#2F92EE;'>#SIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16360, encryptionId=faf7163606a, topicName=SIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Tue Feb 25 16:10:00 CST 2020, time=2020-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1939030, encodeId=e3351939030ae, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Tue Sep 08 03:10:00 CST 2020, time=2020-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1295261, encodeId=1a40129526183, content=<a href='/topic/show?id=0425e2636b8' target=_blank style='color:#2F92EE;'>#真实世界#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72636, encryptionId=0425e2636b8, topicName=真实世界)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b34252, createdName=chenshujs, createdTime=Thu Feb 13 15:10:00 CST 2020, time=2020-02-13, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1826572, encodeId=c33818265e25f, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Fri May 29 15:10:00 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910541, encodeId=d5221910541cb, content=<a href='/topic/show?id=faf7163606a' target=_blank style='color:#2F92EE;'>#SIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16360, encryptionId=faf7163606a, topicName=SIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Tue Feb 25 16:10:00 CST 2020, time=2020-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1939030, encodeId=e3351939030ae, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Tue Sep 08 03:10:00 CST 2020, time=2020-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1295261, encodeId=1a40129526183, content=<a href='/topic/show?id=0425e2636b8' target=_blank style='color:#2F92EE;'>#真实世界#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72636, encryptionId=0425e2636b8, topicName=真实世界)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b34252, createdName=chenshujs, createdTime=Thu Feb 13 15:10:00 CST 2020, time=2020-02-13, status=1, ipAttribution=)]
    2020-02-25 zhanglin3079
  3. [GetPortalCommentsPageByObjectIdResponse(id=1826572, encodeId=c33818265e25f, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Fri May 29 15:10:00 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910541, encodeId=d5221910541cb, content=<a href='/topic/show?id=faf7163606a' target=_blank style='color:#2F92EE;'>#SIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16360, encryptionId=faf7163606a, topicName=SIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Tue Feb 25 16:10:00 CST 2020, time=2020-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1939030, encodeId=e3351939030ae, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Tue Sep 08 03:10:00 CST 2020, time=2020-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1295261, encodeId=1a40129526183, content=<a href='/topic/show?id=0425e2636b8' target=_blank style='color:#2F92EE;'>#真实世界#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72636, encryptionId=0425e2636b8, topicName=真实世界)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b34252, createdName=chenshujs, createdTime=Thu Feb 13 15:10:00 CST 2020, time=2020-02-13, status=1, ipAttribution=)]
    2020-09-08 quxin068
  4. [GetPortalCommentsPageByObjectIdResponse(id=1826572, encodeId=c33818265e25f, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Fri May 29 15:10:00 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1910541, encodeId=d5221910541cb, content=<a href='/topic/show?id=faf7163606a' target=_blank style='color:#2F92EE;'>#SIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16360, encryptionId=faf7163606a, topicName=SIT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Tue Feb 25 16:10:00 CST 2020, time=2020-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1939030, encodeId=e3351939030ae, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Tue Sep 08 03:10:00 CST 2020, time=2020-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1295261, encodeId=1a40129526183, content=<a href='/topic/show?id=0425e2636b8' target=_blank style='color:#2F92EE;'>#真实世界#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72636, encryptionId=0425e2636b8, topicName=真实世界)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b34252, createdName=chenshujs, createdTime=Thu Feb 13 15:10:00 CST 2020, time=2020-02-13, status=1, ipAttribution=)]

相关资讯

NMPA:公开征求《真实世界数据用于医疗器械临床评价技术指导原则》意见

各有关单位:  真实世界数据作为医疗器械临床评价可能的数据来源,因其具有数据资源丰富、研究结果的外推性可能较好、可获得长期临床结局数据等特点,日益受到监管机构、行业等各方重视。2019年4月国家药品监督管理局发布了中国药品监管科学行动计划,把“将真实世界数据用于医疗器械临床评价的方法学研究”列为首批研究项目,探索将真实世界数据用于监管决策的可行性和方法学,为医疗器械审评审批制度改革、加速创新产品的

真实世界证据支持药物研发审评,这四点思考值得关注!

1月7日,国家药监局把2020年的一号文件,留给了此前就备受行业关注的真实世界证据支持药物研发与审评。 在其官网上,药监局同时公布了《真实世界证据支持药物研发与审评指导原则(试行)》,以及该文件的起草说明。作为国内发布的首个真实世界证据支持药物研发与审评的指导文件,这被视为新药研发审评道路上的里程碑事件,并迅速引起了行业的密切关注。事实上,如何利用真实世界证据评价药物的有效性和安全性

ASCO:真实世界中pembrolizumab单抗对NSCLC效果如何联用?

背景:派姆单抗(Pembro)用于转移性非鳞状非小细胞肺癌(NSQ NSCLC)患者的一线治疗,作为单一疗法,并与培美曲塞和铂类药物(Pembro + Pem + Plat)联合使用。对于肿瘤表达PD-L1肿瘤比例评分(TPS)≥1%的患者,批准Pembro单药疗法,而与PD-L1 TPS无关,均批准三联疗法。尚无在头对头试验中对这两种方案进行比较,并且缺乏现实世界(RW)治疗模式数据。这项研究使

真实世界证据支持药物研发的基本考虑(征求意见稿)

真实世界证据支持药物研发的基本考虑(征求意见稿)国家药品监督管理局药品审评中心2019年5月 一、 引言1. 背景与目的随机对照临床试验(Randomized Controlled Trial,RCT)被认为是评价药物有效性的“金标准”,并为药物临床试验普遍采用。RCT严格控制试验入组与排除标准和其它条件,并进行随机化分组,因此能够最大限度地减少影响因果推断的因素,使得研究结论较为确定,所形成

解读真实世界证据时,我们要注意什么?

真实世界数据(Real-world data, RWD)是传统临床试验之外收集的数据,可包括电子病例、患者注册登记数据、医保数据等。真实世界证据(Real-world evidence, RWE)则是基于这些数据的分析与总结。近年来,发布的RWE报告显着增加,在PubMed中对术语“真实世界数据”、“真实世界证据”和“注册登记”的检索显示,2002年至2016年间引用量增加了600%(从每年2,4

真实世界证据支持药物研发与审评的指导原则(试行)

为进一步指导和规范真实世界证据用于支持药物研发和审评的有关工作,保障药物研发工作质量和效率,国家药品监督管理局组织制定了《真实世界证据支持药物研发与审评的指导原则(试行)》,现予发布。 国务院《关于改革药品医疗器械审评审批制度的意见》(国发〔2015〕44号)以及中共中央办公厅、国务院办公厅《关于深化审评审批制度改革鼓励药品医疗器械创新的意见》,均提出鼓励研究和创制新药。随着一系列改革措